Results 31 to 40 of about 1,006,148 (403)
Mutations in pathways depending on BRCA1 and BRCA2 may increase cancer risks from an environmental carcinogen [PDF]
, 2011 Recently, the President’s Cancer Panel [2008-2009] protested that preventive action is not taken when uncertainty exists about potential harm from a chemical, because the US regulatory approach demands that a hazard be incontrovertibly ...
Bernard Friedenson
core +2 more sources
Haematologica, 2011 Background The World Health Organization separates acute erythroid leukemia (erythropoiesis in ≥50% of nucleated bone marrow cells; ≥20% myeloblasts of non-erythroid cells) from other entities with increased erythropoiesis – acute myeloid leukemia with ...
Ulrike Bacher +5 more
doaj +1 more source
Uncommon CD markers in acute myeloid leukemia
Bangabandhu Sheikh Mujib Medical University Journal, 2018 This study was done to assess the unusual CD expression in 100 cases of acute myeloid leukemia from October 2016 to April 2018. The age limit was from 3 to 50 years.
Azad Abul Kalam +3 more
doaj +1 more source
Haematologica, 2008 Acute myeloid leukemia carrying NPM1 mutations and cytoplasmic nucleophosmin (NPMc+ acute myeloid leukemia) represents one-third of adult AML (50–60% of all acute myeloid leukemia with normal karyotype) and shows distinct biological, pathological and ...
Brunangelo Falini +12 more
doaj +1 more source
Frontiers in Oncology, 2022 Myeloid sarcoma is a rare extramedullary tumor of immature myeloid cells. Certain known acute myeloid leukemia cytogenetic abnormalities, in particular t(8,21), has been associated with a higher incidence.
Xuemei Shu +4 more
doaj +1 more source
Blood, 2019 Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and treatment resistance.
C. Dinardo +15 more
semanticscholar +1 more source
Haematologica, 2010 Background C-type lectin-like molecule-1 is a transmembrane receptor expressed on myeloid cells, acute myeloid leukemia blasts and leukemic stem cells.
Xiaoxian Zhao +6 more
doaj +1 more source
Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options [PDF]
, 2018 The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic mechanisms that govern these changes and developing therapeutic approaches to modulate ...
Koschmieder, Steffen, Vetrie, David
core +1 more source
The role of peptide and DNA vaccines in myeloid leukemia immunotherapy
Cancer Cell International, 2013 While chemotherapy and targeted therapy are successful in inducing the remission of myeloid leukemia as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), the disease remains largely incurable.
Lin Chen, Li Yangqiu
doaj +1 more source
The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]
, 2017 Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core +1 more source